

Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H561F37ECA9DEN.html>

Date: December 2022

Pages: 50

Price: US\$ 2,000.00 (Single User License)

ID: H561F37ECA9DEN

Abstracts

Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2022, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hyperphosphatemia In Chronic Kidney Disease - Overview
- Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
- Ardelyx Inc
- China Nuokang Bio-Pharmaceutical Inc
- Citrigen Pharmaceuticals Inc
- OPKO Health Inc
- Panion & Bf Biotech Inc
- Shield Therapeutics Plc
- Unicycive Therapeutics Inc
- Vidasym Inc
- Vifor Pharma Ltd
- Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
- CGN-002 - Drug Profile
- Product Description
- Mechanism Of Action
- fermagate - Drug Profile
- Product Description
- Mechanism Of Action
- ferric citrate - Drug Profile
- Product Description
- Mechanism Of Action
- lanthanum dioxycarbonate - Drug Profile
- Product Description

Mechanism Of Action

lanthanum polystyrene sulfonate - Drug Profile

Product Description

Mechanism Of Action

PT-20 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Hyperphosphatemia - Drug Profile

Product Description

Mechanism Of Action

succharated ferric oxide - Drug Profile

Product Description

Mechanism Of Action

tenapanor hydrochloride - Drug Profile

Product Description

Mechanism Of Action

VS-501 - Drug Profile

Product Description

Mechanism Of Action

Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects

Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products

Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones

Featured News & Press Releases

Nov 10, 2022: Unicycive completes enrollment of pivotal bioequivalence study for RENAZORB (lanthanum dioxycarbonate), an investigational treatment for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis

Nov 06, 2022: Unicycive Therapeutics announces abstract on Renazorb selected for presentation at American Society of Nephrology's Kidney Week 2022

Feb 02, 2022: Unicycive announces Renazorb pre-clinical and clinical data selected for presentation at National Kidney Foundation Spring Clinical Meeting

Nov 29, 2021: Unicycive Therapeutics receives confirmatory guidance on renazorb regulatory pathway

Dec 09, 2020: Akebiashares program: current approaches for managing hyperphosphatemia and caring for patients via telehealth

Jan 28, 2019: Velporo doubles percentage of patients reaching target serum phosphorous levels in new study published in Journal of Renal Nutrition

Jan 06, 2017: Shield Therapeutics Provides Update on PT20

Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting

Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease

May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia

Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology

Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch

Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study

Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by China Nuokang Bio-Pharmaceutical Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Citragen Pharmaceuticals Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Unicycive Therapeutics Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vidasym Inc, 2022

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma Ltd, 2022

Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, 2022

Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H561F37ECA9DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H561F37ECA9DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

